Federico Piacentini

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 366 citations · Full text

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis

Maria Vittoria Dieci, Elena Barbieri, Federico Piacentini et al. · Annals of Oncology · 2012 · 189 citations · Full text

Breast Oncology, Tumor Heterogeneity, Receptor Status +11

Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management

Valentina Guarneri, Simona Giovannelli, Guido Ficarra et al. · The Oncologist · 2008 · 152 citations · Full text

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Pierfranco Conté, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 152 citations · Full text

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Maria Vittoria Dieci, Aleix Prat, Enrico Tagliafico et al. · Annals of Oncology · 2016 · 149 citations · Full text

Breast Oncology, Pam50 Subtypes, Medicine +10